Moderna Inc. ($MRNA) Stock Forecast: Up 5.2% Today

What is Moderna Inc.?

Moderna (NASDAQ: MRNA) is a biotechnology company renowned for its mRNA technology, particularly in the development of vaccines like the COVID-19 vaccine.

Why is Moderna Inc. going up?

MRNA stock is up 5.2% on Jan 13, 2025 20:57

• Moderna demonstrated a strong bullish movement today despite revising its 2025 sales forecast downwards, showcasing resilience in the market.
• Investor interest in vaccine-related stocks, including Moderna, surged following reports of the first US bird-flu fatality, highlighting the company's expertise in vaccine innovation.
• The increase in Moderna's stock price is potentially influenced by positive investor sentiment and speculative trading rather than firm financial performance given the adjusted sales outlook.
• Notwithstanding the reduced sales forecast, Moderna's stock price saw a significant rise, suggesting that market mood and external factors may have driven today's bullish trend.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives - Moderna ( NASDAQ:MRNA )

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $3 billion in Spikevax sales and minimal mRESVIA contributions. Moderna Inc.

https://www.benzinga.com/25/01/42946454/moderna-expects-lower-annual-sales-expands-cost-cutting-initiatives

Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.

https://www.cnbc.com/2025/01/13/moderna-lowers-2025-sales-forecast.html

Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death

The first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines.

https://www.zacks.com/stock/news/2393432/vaccine-stocks-jump-after-cdc-reports-first-us-bird-flu-death

Moderna ( MRNA ) Stock Jumps 11.7%: Will It Continue to Soar?

Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

https://www.zacks.com/stock/news/2393410/moderna-mrna-stock-jumps-117-will-it-continue-to-soar

Company News for Jan 8, 2025

Companies In The News Are: RPM, LNN, TSLA, MRNA.

https://www.zacks.com/stock/news/2393368/company-news-for-jan-8-2025

Trending Today

Bittensor ($TAO) Crypto Forecast: Up 5.6% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.3% Today

McKesson Corporation ($MCK) Stock Forecast: Up 0.6% Today

Toncoin ($TON) Crypto Forecast: Up 5.1% Today

Sonic (prev. FTM) ($S) Crypto Forecast: Up 14.4% Today

Dogecoin ($DOGE) Crypto Forecast: Up 11.3% Today

Arkham ($ARKM) Crypto Forecast: Up 8.2% Today

Solana ($SOL) Crypto Forecast: Up 6.0% Today

Ethereum ($ETH) Crypto Forecast: Up 6.9% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 9.7% Today

Moderna Inc. Price History

18.10.2024 - MRNA Stock was up 5.1%

• Moderna's stock saw an impressive rise today despite ongoing questions about vaccine safety and the appointment of Robert F. Kennedy Jr. for leadership in the Department of Health and Human Services.
• Market response appeared favorable, potentially due to Moderna's unwavering belief in its products and competence to manage political obstacles.
• Investors may have construed Moderna's ability to withstand political uncertainties as a mark of robustness and future sustainability, contributing to the positive market trend.
• Despite initial worries, Moderna's stock exhibited resilience and gained momentum, underscoring investor trust in the company's future outlook.

07.00.2025 - MRNA Stock was up 7.3%

• Moderna stock saw a 4.0% increase in trading today.
• Speculation on a surge in acute respiratory illnesses in the United States by the CDC may have positively influenced investor sentiment towards Moderna due to its role in vaccine development.
• Despite some bearish options trading, the overall market response and anticipated demand for Moderna's offerings appeared to drive the bullish uptrend in the stock price.

07.00.2025 - MRNA Stock was up 7.8%

• Moderna (MRNA) experienced a strong bullish movement today amidst the following developments:
• The US recorded its first human death from the H5N1 bird flu virus, leading to a rally in vaccine stocks like Novavax (NVAX).
• High levels of respiratory illnesses reported by the CDC boosted the demand for vaccine-related companies.
• Financial giants showed bullish sentiment towards Moderna, with a majority of traders displaying optimism in options trading.
• The CDC's report on the rise in acute respiratory illnesses across the US likely contributed to the positive market sentiment towards Moderna.
• Despite lagging behind the overall market, Moderna's stock price saw a notable increase, indicating investor confidence in the company's future prospects.

18.11.2024 - MRNA Stock was down 6.1%

• Moderna's stock showed a decline, potentially linked to its removal from the Nasdaq-100 Index, prompting a decrease in investor confidence.
• The spotlight on Sanofi's vaccine candidates for COVID-19 and influenza with the Fast Track designation may have shifted investor focus from Moderna, impacting its stock negatively.
• Today's bearish movement in MRNA stock might have been influenced by the market response to Moderna's index removal and the positive developments related to Sanofi's vaccine candidates.

06.11.2024 - MRNA Stock was up 6.4%

• The positive sentiment surrounding Moderna's latest Covid-19 vaccine update possibly drove the stock's bullish movement, despite some reluctance among Hong Kong residents.
• Moderna's stock performance could have been influenced by its recent inclusion among the top 10 large-cap gainers last week, alongside companies like Rivian Automotive and Rocket Lab.
• Investor confidence in Moderna's ongoing success in the biotech industry, especially amidst global vaccination initiatives, likely played a role in today's strong stock performance.

26.10.2024 - MRNA Stock was down 5.5%

• Moderna's stock experienced a bearish movement today, possibly due to:
• Profit-taking by investors after a period of strong performance, as indicated by the bearish stance taken by significant traders in options trading.
• Concerns about the spread of a mutated bird flu case in California, which could increase the urgency for vaccine development and potentially impact Moderna's competitive position in the market.
• Market volatility and overall sentiment affecting biotech stocks, leading to a broader sell-off in the sector.

10.11.2024 - MRNA Stock was down 5.0%

• The downward trend in Moderna's stock price today may be linked to reports of hesitation among Hong Kong residents regarding the latest Covid-19 vaccine offered by the company. This apprehension could have sparked concerns among investors about the potential impact on Moderna's vaccine sales and revenue.
• Moreover, a shift in options trading activities towards a negative stance by affluent investors could have exacerbated the pessimistic sentiment surrounding Moderna's stock, contributing to the notable decline witnessed today.
• These combined factors likely influenced the bearish perspective on Moderna's stock, underscoring the significance of public perception and investor sentiment in shaping market dynamics, particularly within the pharmaceutical industry.

19.10.2024 - MRNA Stock was down 5.0%

• Moderna's stock saw a decline today despite the company's strong belief in the efficacy of its vaccines.
• Political worries regarding vaccine safety and the appointment of Robert F. Kennedy Jr. to head the Department of Health and Human Services might have influenced the negative market mood.
• Attention on Moderna's rivals and legal troubles encountered by other companies like Metagenomi (NASDAQ: MGX) could have impacted investor faith in Moderna's stock.
• All in all, the mix of political uncertainties and legal issues in the biotech industry likely affected Moderna's downward trend in the market today.

11.11.2024 - MRNA Stock was down 5.1%

• Investor focus may have shifted due to Novavax's announcement of a late-stage study on a COVID-19-flu combo and flu vaccines, potentially impacting Moderna's stock negatively.
• Options trading trends suggest a bearish sentiment from deep-pocketed investors towards Moderna, which could have contributed to the stock's decline.
• Market reaction indicates that investors are closely monitoring developments in the biotech and vaccine landscape, making them highly responsive to news affecting Moderna's competitive position.

21.10.2024 - MRNA Stock was up 5.4%

• The appearance of a mutated bird flu case in California has drawn attention to vaccine development companies, including Moderna. This development likely bolstered investor confidence in Moderna's ability to address new health threats effectively.
• Despite some bearish options trading activities, Moderna's overall positive performance can be linked to the company's ongoing faith in its vaccine technology, particularly amidst public concerns regarding vaccine safety and changes in health leadership.
• The unfavorable investor sentiment towards companies like Metagenomi (NASDAQ: MGX) following class action lawsuits and shareholder alerts may have shifted investor focus towards established players such as Moderna, contributing to its strong performance today.

08.00.2025 - MRNA Stock was down 5.3%

• Despite positive news related to vaccine stocks and the CDC's report on the first US bird-flu death, Moderna's stock experienced strong bearish movement.
• Although there was a significant increase in options activity, with a majority of traders adopting a bullish stance, it did not result in a sustained uptrend for Moderna's stock.
• The recent trend in earnings estimate revisions suggested no signs of further strength, leading to negative market reactions possibly driven by concerns regarding the company's future earnings potential.
• Investors might be exhibiting caution regarding Moderna's ability to seize opportunities in the current vaccine market amidst competition and market volatility triggered by the news of the first human bird flu death in the US.

13.00.2025 - MRNA Stock was up 5.2%

• Moderna demonstrated a strong bullish movement today despite revising its 2025 sales forecast downwards, showcasing resilience in the market.
• Investor interest in vaccine-related stocks, including Moderna, surged following reports of the first US bird-flu fatality, highlighting the company's expertise in vaccine innovation.
• The increase in Moderna's stock price is potentially influenced by positive investor sentiment and speculative trading rather than firm financial performance given the adjusted sales outlook.
• Notwithstanding the reduced sales forecast, Moderna's stock price saw a significant rise, suggesting that market mood and external factors may have driven today's bullish trend.